Meta AnalysisID 5907
参桂胶囊治疗慢性心力衰竭的疗效与安全性评价：随机对照试验的系统评价与Meta分析
CRD42023390409
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Shengui capsule for coronary heart failure
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5907
- Evidence Id
- 14465
- Core Evidence Id
- 14465
- Source Meta Analysis Id
- 5890
- Herb2 Meta Analysis Id
- HBMA005890
- Crd Id
- CRD42023390409
- Title
- Efficacy and safety evaluation of Shengui capsule for chronic heart failure: A systematic review and meta-analysis of randomised controlled trials
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Shengui capsule for coronary heart failure
- Study Type Included
- Randomized controlled trials (RCTs) will be included.
- Condition Being Studied
- Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age, which characterized by dyspnea, fatigue, and signs of volume overload. Many conditions, such as coronary artery disease, hypertension, valvular heart disease, and diabetes mellitus, can cause or lead to decompensation of chronic heart failure. Especially, coronary artery disease is the most common cause of heart failure. Studies have shown that complementary and alternative therapy plays an advantage in improving symptoms and reducing side effects in patients with coronary heart failure (CHF). Shengui capsule is widely used in the treatment of CHF in China.
- Participant
- Adults with coronary heart failure (as diagnosed by a clinician, or using any recognized diagnostic criteria) will be included.
- Animal
- Human Disease Modelled
- Intervention
- Shengui capsule is the main intervention.
- Comparator Control
- Usual care and medications such as diuretics, angiotensin converting enzyme inhibitors (ACEIs), or angiotensin II receptor blockers (ARBs), β-receptor blocker, aldosterone-receptor blocker, digoxin, etc.
- Main Outcome
- LVEF, adverse events
- Outcome Measure
- Additional Outcome
- LVESD, LVEDD, brain natriuretic peptide (BNP), hs-CRP, effective rate of heart function improvement
- Study Method
- Keyword
- Chronic Disease; Heart; Heart Failure; Humans; Randomized Controlled Trials as Topic; Thorax
- Contact
- Jiaqi Yan [email protected]
- Organisational Affiliation
- Guangzhou University of Chinese Medicine
- Funding Source
- This work is funded by the grants from the National Natural Science Foundation of China (No.82174156), Guangzhou Science and Technology Project (No. 202002030432), and Key-Area Research and Development Program of Guangdong Province (No.2020B1111100004).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-01-09
- Registration Date
- 2023-01-20
- Anticipated Start Date
- 2023-01-09
- Anticipated Completion Date
- 2024-01-03
- Title Cn
- 参桂胶囊治疗慢性心力衰竭的疗效与安全性评价：随机对照试验的系统评价与Meta分析
- Title En
- Efficacy and safety evaluation of Shengui capsule for chronic heart failure: A systematic review and meta-analysis of randomised controlled trials
- Bilingual Status
- complete